Download
Kashte2021_Article_COVID-19VaccinesRapidDevelopme.pdf 1,02MB
WeightNameValue
1000 Titel
  • COVID-19 vaccines: rapid development, implications, challenges and future prospects
1000 Autor/in
  1. Kashte, Shivaji |
  2. Gulbake, Arvind |
  3. El-Amin III, Saadiq F. |
  4. Gupta, Ashim |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-03-07
1000 Erschienen in
1000 Quellenangabe
  • 34(3):711-733
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s13577-021-00512-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937046/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • COVID-19 has affected millions of people and put an unparalleled burden on healthcare systems as well as economies throughout the world. Currently, there is no decisive therapy for COVID-19 or related complications. The only hope to mitigate this pandemic is through vaccines. The COVID-19 vaccines are being developed rapidly, compared to traditional vaccines, and are being approved via Emergency Use Authorization (EUA) worldwide. So far, there are 232 vaccine candidates. One hundred and seventy-two are in preclinical development and 60 in clinical development, of which 9 are approved under EUA by different countries. This includes the United Kingdom (UK), United States of America (USA), Canada, Russia, China, and India. Distributing vaccination to all, with a safe and efficacious vaccine is the leading priority for all nations to combat this COVID-19 pandemic. However, the current accelerated process of COVID-19 vaccine development and EUA has many unanswered questions. In addition, the change in strain of SARS-CoV-2 in UK and South Africa, and its increasing spread across the world have raised more challenges, both for the vaccine developers as well as the governments across the world. In this review, we have discussed the different type of vaccines with examples of COVID-19 vaccines, their rapid development compared to the traditional vaccine, associated challenges, and future prospects.
1000 Sacherschließung
lokal Emergency use authorization
gnd 1206347392 COVID-19
lokal COVID-19 vaccine
lokal SARS-Cov-2
lokal Vaccine hesitancy
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S2FzaHRlLCBTaGl2YWpp|https://frl.publisso.de/adhoc/uri/R3VsYmFrZSwgQXJ2aW5k|https://frl.publisso.de/adhoc/uri/RWwtQW1pbiBJSUksIFNhYWRpcSBGLg==|https://orcid.org/0000-0003-1224-2755
1000 Label
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. -
1000 Dateien
  1. COVID-19 vaccines: rapid development, implications, challenges and future prospects
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6427490.rdf
1000 Erstellt am 2021-05-14T13:15:06.366+0200
1000 Erstellt von 218
1000 beschreibt frl:6427490
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet Tue May 17 07:12:14 CEST 2022
1000 Objekt bearb. Tue May 17 07:11:48 CEST 2022
1000 Vgl. frl:6427490
1000 Oai Id
  1. oai:frl.publisso.de:frl:6427490 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source